SCHEMBL30296188

SCHEMBL30296188

COc1ccc(CNc2cc(Cl)c(C3(O)CC3)cc2F)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 1/20 0.44
▸ APLNR P35414 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.43
▸ TSHR P16473 5/20 0.41
▸ CYP1A2 P05177 4/20 0.41
▸ CYP3A4 P08684 4/20 0.41
▸ CYP2D6 P10635 4/20 0.41
▸ CYP2C19 P33261 4/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ CLK4 Q9HAZ1 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LMNA P02545 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296407 0.78 KDM4C (0.54) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL15435400 0.73 GAA (0.54) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL19728818 0.72 APLNR (0.49) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL21341283 0.72 APLNR (0.49) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL20157455 0.72 APLNR (0.49) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL21262083 0.71 CYP1A2 (0.59) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL15435347 0.71 APLNR (0.51) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL21362495 0.71 APLNR (0.51) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL28273319 0.71 APLNR (0.54) MEN1KMT2AMAPTAPLNRKDM4C
SCHEMBL31185318 0.71 APLNR (0.50) MEN1KMT2AMAPTAPLNRKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 — — US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 — — EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 — — CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MEN1 4599/4885KMT2A 3316/4885MAPT 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback